Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Verastem Inc

VSTM ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$6.89

▲ +1.03%

Market Cap $623.98M · Vol 338.43K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$623.98M

Small Cap

Div Yield

N/A

EPS Growth

+47.60%

YoY

RSI (14)

67.86

Momentum

Beta

0.31

vs Market

52W High

$11.24

38.70% below

52W Low

$3.43

100.87% above

Volume

338.43K

Avg 721.30K

P/B

10.49

Price-to-book

ROE

N/A

Return on equity

Free Float

94.02%

Public shares

Shariah Compliance8 STANDARDS

✗ Verastem Inc (VSTM) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does VSTM pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+4.71%

+14.83%

+61.36%

+16.19%

YTD

-10.75%

-20.16%

-29.48%

-77.57%

Financials & Valuation

TTM · Annual

Total Revenue	$30.91M
Net Income	$-209,471,000.00
Revenue Growth (YoY)	+1,775.43%
Gross Margin	82.86%
Operating Margin	-550.33%
Net Profit Margin	-677.59%
ROE	N/A
ROA · ROIC	-120.39% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	17.31
P/B	10.49
P/FCF	N/A
EPS Growth	+47.60%
Outstanding Shares	90.56M

Technical Indicators

50-Day SMA	$5.47
200-Day SMA	$6.28
RSI (14)	67.86
Beta	0.31
52-Week High	$11.24
52-Week Low	$3.43

Volume Today	338.43K
Avg Daily Volume (30D)	721.30K
Relative Volume	0.47x
Volatility (10D)	65.69
Volatility (30D)	65.04
Free Float	94.02%

Analyst Consensus

BUY

Current Price $6.89

Mean Target $14.75

52W Low$3.43 52W High$11.24

Current

Target

$3.43 $11.24

Current Analyst target

+114.08% upside potential · 9 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001V0G978

ISINUS92337C2035

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -0.39% ARGX.BR argenx SE +1.90% ARGX argenx SE +0.16% INSM Insmed Inc +0.55% 2269.HK WuXi Biologics (Cayman) Inc +2.74%

Company Profile

Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.